Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Design and Sample Collection
2.2. MiRNA Extraction
2.3. Retrotranscription and Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR)
2.4. Target Prediction Analysis
2.5. Statistical Analysis
3. Results
3.1. Study Workflow
3.2. Circulating miR-30b-5p and miR-99a-5p Levels in Plasma Samples from BC and Healthy Patients
3.3. Two-MicroRNA Signature as a Potential Diagnostic Biomarker in Very Early-Stage BC Patients
3.4. Validation of Plasma miRNA Signature as an Early Diagnosis BC Biomarker
3.5. Functional Enrichment Analysis for miR-30b-5p and miR-99a-5p
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ginsburg, O.; Yip, C.; Brooks, A.; Cabanes, A.; Caleffi, M.; Yataco, J.A.D.; Gyawali, B.; McCormack, V.; de Anderson, M.M.; Mehrotra, R.; et al. Breast cancer early detection: A phased approach to implementation. Cancer 2020, 126, 2379–2393. [Google Scholar] [CrossRef] [PubMed]
- Miller, K.D.; Nogueira, L.; Mariotto, A.B.; Rowland, J.H.; Yabroff, K.R.; Alfano, C.M.; Jemal, A.; Kramer, J.L.; Siegel, R.L. Cancer treatment and survivorship statistics, 2019. CA Cancer J. Clin. 2019, 69, 363–385. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hellquist, B.N.; Czene, K.; Hjälm, A.; Nyström, L.; Jönsson, H. Effectiveness of population-based service screening with mammography for women ages 40 to 49 years with a high or low risk of breast cancer: Socioeconomic status, parity, and age at birth of first child. Cancer 2015, 121, 251–258. [Google Scholar] [CrossRef]
- Wang, L. Early Diagnosis of Breast Cancer. Sensors 2017, 17, 1572. [Google Scholar] [CrossRef]
- Ramassone, A.; Pagotto, S.; Veronese, A.; Visone, R. Epigenetics and MicroRNAs in Cancer. Int. J. Mol. Sci. 2018, 19, 459. [Google Scholar] [CrossRef] [Green Version]
- Ozawa, P.M.M.; Jucoski, T.S.; Vieira, E.; Carvalho, T.M.; Malheiros, D.; Ribeiro, E.M.D.S.F. Liquid biopsy for breast cancer using extracellular vesicles and cell-free microRNAs as biomarkers. Transl. Res. 2020, 223, 40–60. [Google Scholar] [CrossRef] [PubMed]
- Peng, Y.; Croce, C.M. The role of MicroRNAs in human cancer. Signal Transduct. Target. 2016, 1, 15004. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Baranwal, S.; Alahari, S.K. miRNA control of tumor cell invasion and metastasis. Int. J. Cancer 2010, 126, 1283–1290. [Google Scholar] [CrossRef] [PubMed]
- Tormo, E.; Adam-Artigues, A.; Ballester, S.; Pineda, B.; Zazo, S.; González-Alonso, P.; Albanell, J.; Rovira, A.; Rojo, F.; Lluch, A.; et al. The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene. Sci. Rep. 2017, 7. [Google Scholar] [CrossRef] [PubMed]
- Tormo, E.; Ballester, S.; Adam-Artigues, A.; Burgués, O.; Alonso, E.; Bermejo, B.; Menéndez, S.; Zazo, S.; Madoz-Gúrpide, J.; Rovira, A.; et al. The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors. Sci. Rep. 2019, 9. [Google Scholar] [CrossRef] [Green Version]
- Hayes, J.; Peruzzi, P.P.; Lawler, S. MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol. Med. 2014, 20, 460–469. [Google Scholar] [CrossRef]
- Bidarra, D.; Constâncio, V.; Barros-Silva, D.; Ramalho-Carvalho, J.; Moreira-Barbosa, C.; Antunes, L.; Maurício, J.; Oliveira, J.; Henrique, R.; Jerónimo, C. Circulating MicroRNAs as Biomarkers for Prostate Cancer Detection and Metastasis Development Prediction. Front. Oncol. 2019, 9, 900. [Google Scholar] [CrossRef] [Green Version]
- Ng, E.K.O.; Li, R.; Shin, V.Y.; Jin, H.C.; Leung, C.P.H.; Ma, E.S.K.; Pang, R.; Chua, D.; Chu, K.M.; Law, W.L.; et al. Circulating microRNAs as Specific Biomarkers for Breast Cancer Detection. PLoS ONE 2013, 8, e53141. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Alba-Bernal, A.; Lavado-Valenzuela, R.; Domínguez-Recio, M.E.; Jiménez-Rodriguez, B.; Queipo-Ortuño, M.I.; Alba, E.; Comino-Méndez, I. Challenges and achievements of liquid biopsy technologies employed in early breast cancer. EBioMedicine 2020, 62, 103100. [Google Scholar] [CrossRef]
- Hojbjerg, J.A.; Ebert, E.B.F.; Clement, M.S.; Winther-Larsen, A.; Meldgaard, P.; Sorensen, B. Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients. Lung Cancer 2019, 135, 92–96. [Google Scholar] [CrossRef] [Green Version]
- Ni, Q.; Stevic, I.; Pan, C.; Müller, V.; Oliviera-Ferrer, L.; Pantel, K.; Schwarzenbach, H. Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients. Sci. Rep. 2018, 8. [Google Scholar] [CrossRef] [PubMed]
- Li, C.; Qin, F.; Hu, F.; Xu, H.; Sun, G.; Han, G.; Wang, T.; Guo, M. Characterization and selective incorporation of small non-coding RNAs in non-small cell lung cancer extracellular vesicles. Cell Biosci. 2018, 8, 2. [Google Scholar] [CrossRef] [Green Version]
- Adam-Artigues, A.; Garrido-Cano, I.; Simón, S.; Ortega, B.; Moragón, S.; Lameirinhas, A.; Constâncio, V.; Salta, S.; Burgués, O.; Bermejo, B.; et al. Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer. ESMO Open 2021, 6, 100039. [Google Scholar] [CrossRef] [PubMed]
- Feng, Y.; Kang, Y.; He, Y.; Liu, J.; Liang, B.; Yang, P.; Yu, Z. MicroRNA-99a acts as a tumor suppressor and is down-regulated in bladder cancer. BMC Urol. 2014, 14. [Google Scholar] [CrossRef] [Green Version]
- Holubekova, V.; Kolkova, Z.; Grendar, M.; Brany, D.; Dvorska, D.; Stastny, I.; Jagelkova, M.; Zelinova, K.; Samec, M.; Liskova, A.; et al. Pathway analysis of selected circulating mirnas in plasma of breast cancer patients: A preliminary study. Int. J. Mol. Sci. 2020, 21, 7288. [Google Scholar] [CrossRef] [PubMed]
- Garrido-Cano, I.; Constâncio, V.; Adam-Artigues, A.; Lameirinhas, A.; Simón, S.; Ortega, B.; Martínez, M.T.; Hernando, C.; Bermejo, B.; Lluch, A.; et al. Circulating mir-99a-5p expression in plasma: A potential biomarker for early diagnosis of breast cancer. Int. J. Mol. Sci. 2020, 21, 7427. [Google Scholar] [CrossRef] [PubMed]
- Hou, B.; Ishinaga, H.; Midorikawa, K.; Shah, S.A.; Nakamura, S.; Hiraku, Y.; Oikawa, S.; Murata, M.; Takeuchi, K. Circulating microRNAs as novel prognosis biomarkers for head and neck squamous cell carcinoma. Cancer Biol. Ther. 2015, 16, 1042–1046. [Google Scholar] [CrossRef]
- Gablo, N.; Trachtova, K.; Prochazka, V.; Hlavsa, J.; Grolich, T.; Kiss, I.; Srovnal, J.; Rehulkova, A.; Lovecek, M.; Skalicky, P.; et al. Identification and Validation of Circulating Micrornas as Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma Patients Undergoing Surgical Resection. J. Clin. Med. 2020, 9, 2440. [Google Scholar] [CrossRef] [PubMed]
- Vlachos, I.S.; Zagganas, K.; Paraskevopoulou, M.D.; Georgakilas, G.; Karagkouni, D.; Vergoulis, T.; Dalamagas, T.; Hatzigeorgiou, A.G. DIANA-miRPath v3.0: Deciphering microRNA function with experimental support. Nucleic Acids Res. 2015, 43, W460–W466. [Google Scholar] [CrossRef] [PubMed]
- Youden, W.J. Index for rating diagnostic tests. Cancer 1950, 3, 32–35. [Google Scholar] [CrossRef]
- Amin, M.B.; Gress, D.M.; Vega, L.R.M.; Edge, S.B.; Greene, F.L.; Byrd, D.R.; Brookland, R.K.; Washington, M.K.; Compton, C.C. AJCC Cancer Staging Manual, 8th ed.; Springer: New York, NY, USA, 2018. [Google Scholar]
- Underwood, J.J.; Quadri, R.S.; Kalva, S.P.; Shah, H.; Sanjeeviah, A.R.; Beg, M.S.; Sutphin, P.D. Liquid biopsy for cancer: Review and implications for the radiologist. Radiology 2020, 294, 5–17. [Google Scholar] [CrossRef]
- Chen, L.; Bode, A.M.; Dong, Z. Circulating tumor cells: Moving biological insights into detection. Theranostics 2017, 7, 2606–2619. [Google Scholar] [CrossRef]
- Sumanasuriya, S.; Lambros, M.B.; de Bono, J.S. Application of Liquid Biopsies in Cancer Targeted Therapy. Clin. Pharmacol. Ther. 2017, 102, 745–747. [Google Scholar] [CrossRef] [PubMed]
- Cohen, S.J.; Punt, C.J.A.; Iannotti, N.; Saidman, B.H.; Sabbath, K.D.; Gabrail, N.Y.; Picus, J.; Morse, M.; Mitchell, E.; Miller, M.C.; et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26, 3213–3221. [Google Scholar] [CrossRef] [PubMed]
- Cristofanilli, M.; Hayes, D.F.; Budd, G.T.; Ellis, M.J.; Stopeck, A.; Reuben, J.M.; Doyle, G.V.; Matera, J.; Allard, W.J.; Miller, M.C.; et al. Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol. 2005, 23, 1420–1430. [Google Scholar] [CrossRef] [PubMed]
- De Bono, J.S.; Scher, H.I.; Montgomery, R.B.; Parker, C.; Miller, M.C.; Tissing, H.; Doyle, G.V.; Terstappen, L.W.W.M.; Pienta, K.J.; Raghavan, D. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 2008, 14, 6302–6309. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-agadjanyan, E.L.; Peterson, A.; Noteboom, J.; Briant, K.C.O.; Allen, A.; et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105, 10513–10518. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zubor, P.; Kubatka, P.; Kajo, K.; Dankova, Z.; Polacek, H.; Bielik, T.; Kudela, E.; Samec, M.; Liskova, A.; Vlcakova, D.; et al. Why the gold standard approach by mammography demands extension by multiomics? Application of liquid biopsy mirna profiles to breast cancer disease management. Int. J. Mol. Sci. 2019, 20, 2878. [Google Scholar] [CrossRef] [Green Version]
- Adam, L.; Wszolek, M.F.; Liu, C.G.; Jing, W.; Diao, L.; Zien, A.; Zhang, J.D.; Jackson, D.; Dinney, C.P.N. Plasma microRNA profiles for bladder cancer detection. Urol. Oncol. Semin. Orig. Investig. 2013, 31, 1701–1708. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ma, G.; Song, G.; Zou, X.; Shan, X.; Liu, Q.; Xia, T.; Zhou, X.; Zhu, W. Circulating plasma microRNA signature for the diagnosis of cervical cancer. Cancer Biomark. 2019, 26, 491–500. [Google Scholar] [CrossRef] [PubMed]
- Silva, C.M.S.; Barros-Filho, M.C.; Wong, D.V.T.; Mello, J.B.H.; Nobre, L.M.S.; Wanderley, C.W.S.; Lucetti, L.T.; Muniz, H.A.; Paiva, I.K.D.; Kuasne, H.; et al. Circulating let-7e-5p, mir-106a-5p, mir-28-3p, and mir-542-5p as a promising microrna signature for the detection of colorectal cancer. Cancers 2021, 13, 1493. [Google Scholar] [CrossRef] [PubMed]
- Herreros-Villanueva, M.; Duran-Sanchon, S.; Martín, A.C.; Pérez-Palacios, R.; Vila-Navarro, E.; Marcuello, M.; Diaz-Centeno, M.; Cubiella, J.; Diez, M.S.; Bujanda, L.; et al. Plasma MicroRNA Signature Validation for Early Detection of Colorectal Cancer. Clin. Transl. Gastroenterol. 2019, 10, e00003. [Google Scholar] [CrossRef] [PubMed]
- Zanutto, S.; Ciniselli, C.M.; Belfiore, A.; Lecchi, M.; Masci, E.; Delconte, G.; Primignani, M.; Tosetti, G.; Dal Fante, M.; Fazzini, L.; et al. Plasma miRNA-based signatures in CRC screening programs. Int. J. Cancer 2020, 146, 1164–1173. [Google Scholar] [CrossRef] [Green Version]
- Shin, V.Y.; Ng, E.K.O.; Chan, V.W.; Kwong, A.; Chu, K.M. A three-miRNA signature as promising non-invasive diagnostic marker for gastric cancer. Mol. Cancer 2015, 14. [Google Scholar] [CrossRef] [Green Version]
- Zhou, X.; Zhu, W.; Li, H.; Wen, W.; Cheng, W.; Wang, F.; Wu, Y.; Qi, L.; Fan, Y.; Chen, Y.; et al. Diagnostic value of a plasma microRNA signature in gastric cancer: A microRNA expression analysis. Sci. Rep. 2015, 5. [Google Scholar] [CrossRef]
- Zhou, X.; Lu, Z.; Wang, T.; Huang, Z.; Zhu, W.; Miao, Y. Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis. Gene 2018, 673, 181–193. [Google Scholar] [CrossRef]
- Ouyang, L.; Liu, P.; Yang, S.; Ye, S.; Xu, W.; Liu, X. A three-plasma miRNA signature serves as novel biomarkers for osteosarcoma. Med. Oncol. 2013, 30. [Google Scholar] [CrossRef] [PubMed]
- Chang, Y.A.; Weng, S.L.; Yang, S.F.; Chou, C.H.; Huang, W.C.; Tu, S.J.; Chang, T.H.; Huang, C.N.; Jong, Y.J.; Huang, H. Da A three–MicroRNA signature as a potential biomarker for the early detection of oral cancer. Int. J. Mol. Sci. 2018, 19, 758. [Google Scholar] [CrossRef] [Green Version]
- Zhuo, X.; Zhou, W.; Li, D.; Chang, A.; Wang, Y.; Wu, Y.; Zhou, Q. Plasma microRNA expression signature involving miR-548q, miR-630 and miR-940 as biomarkers for nasopharyngeal carcinoma detection. Cancer Biomark. 2018, 23, 579–587. [Google Scholar] [CrossRef] [PubMed]
- Leng, Q.; Lin, Y.; Jiang, F.; Lee, C.J.; Zhan, M.; Fang, H.B.; Wang, Y.; Jiang, F. A plasma miRNA signature for lung cancer early detection. Oncotarget 2017, 8, 111902–111911. [Google Scholar] [CrossRef] [Green Version]
- Shen, J.; Hu, Q.; Schrauder, M.; Yan, L.; Wang, D.; Medico, L.; Guo, Y.; Yao, S.; Zhu, Q.; Liu, B.; et al. Circulating miR-148b and miR-133a as biomarkers for breast cancer detection. Oncotarget 2014, 5, 5284–5294. [Google Scholar] [CrossRef] [Green Version]
- Cuk, K.; Zucknick, M.; Heil, J.; Madhavan, D.; Schott, S.; Turchinovich, A.; Arlt, D.; Rath, M.; Sohn, C.; Benner, A.; et al. Circulating microRNAs in plasma as early detection markers for breast cancer. Int. J. Cancer 2013, 132, 1602–1612. [Google Scholar] [CrossRef] [PubMed]
- Li, X.; Zou, W.; Wang, Y.; Liao, Z.; Li, L.; Zhai, Y.; Zhang, L.; Gu, S.; Zhao, X. Plasma-based microRNA signatures in early diagnosis of breast cancer. Mol. Genet. Genom. Med. 2020, 8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Frères, P.; Wenric, S.; Boukerroucha, M.; Fasquelle, C.; Thiry, J.; Bovy, N.; Struman, I.; Geurts, P.; Collignon, J.; Schroeder, H.; et al. Circulating microRNA-based screening tool for breast cancer. Oncotarget 2016, 7, 5416–5428. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, M.; Zhou, Y.; Xia, T.; Zhou, X.; Huang, Z.; Zhang, H.; Zhu, W.; Ding, Q.; Wang, S. Circulating microRNAs from the miR-106a–363 cluster on chromosome X as novel diagnostic biomarkers for breast cancer. Breast Cancer Res. Treat. 2018, 170, 257–270. [Google Scholar] [CrossRef]
- Fang, R.; Zhu, Y.; Hu, L.; Khadka, V.S.; Ai, J.; Zou, H.; Ju, D.; Jiang, B.; Deng, Y.; Hu, X. Plasma microRNA pair panels as novel biomarkers for detection of early stage breast cancer. Front. Physiol. 2019, 10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kastenhuber, E.R.; Lowe, S.W. Putting p53 in Context. Cell 2017, 170, 1062–1078. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lowe, S.W.; Jacks, T.; Housman, D.E.; Ruley, H.E. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc. Natl. Acad. Sci. USA 1994, 91, 2026–2030. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- McGranahan, N.; Swanton, C. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell 2017, 168, 613–628. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Walerych, D.; Napoli, M.; Collavin, L.; Del Sal, G. The rebel angel: Mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 2012, 33, 2007–2017. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Duffy, M.J.; Synnott, N.C.; McGowan, P.M.; Crown, J.; O’Connor, D.; Gallagher, W.M. P53 as a target for the treatment of cancer. Cancer Treat. Rev. 2014, 40, 1153–1160. [Google Scholar] [CrossRef]
- Yu, Q.C.; Verheyen, E.M.; Zeng, Y.A. Mammary development and breast cancer: A Wnt perspective. Cancers 2016, 8, 65. [Google Scholar] [CrossRef] [Green Version]
- Hou, M.F.; Chen, P.M.; Chu, P.Y. LGR5 overexpression confers poor relapse-free survival in breast cancer patients. BMC Cancer 2018, 18. [Google Scholar] [CrossRef] [Green Version]
- Zhang, S.; Zhang, H.; Ghia, E.M.; Huang, J.; Wu, L.; Zhang, J.; Lam, S.; Lei, Y.; He, J.; Cui, B.; et al. Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody. Proc. Natl. Acad. Sci. USA 2019, 116, 1370–1377. [Google Scholar] [CrossRef] [Green Version]
- Castagnoli, L.; Tagliabue, E.; Pupa, S.M. Inhibition of the Wnt signalling pathway: An avenue to control breast cancer aggressiveness. Int. J. Mol. Sci. 2020, 21, 9069. [Google Scholar] [CrossRef] [PubMed]
- van Schie, E.H.; van Amerongen, R. Aberrant WNT/CTNNB1 Signaling as a Therapeutic Target in Human Breast Cancer: Weighing the Evidence. Front. Cell Dev. Biol. 2020, 8. [Google Scholar] [CrossRef] [PubMed]
Characteristics | N (%) | Median (95% CI) | p Value (vs. Control) | p Value |
---|---|---|---|---|
Healthy controls | 89 | 0.6787 (0.3943–1.234) | ||
BC patients | 54 | 0.2593 (0.2073–0.3098) | <0.0001 | |
Molecular subtype | ||||
Luminal | 32 (59.26%) | 0.7656 (0.3228–1.383) | <0.0001 | 0.2750 |
TNBC | 10 (18.52%) | 0.4252 (0.1722–1.177) | 0.02 | |
HER2 | 12 (22.22%) | 1.233 (0.4249–2.229) | <0.0001 | |
Grade | ||||
1 | 2 (3.70%) | 0.3232 (0.2711–0.3753) | 0.9697 | 0.4094 |
2 | 24 (44.44%) | 0.8368 (0.3654–1.954) | <0.0001 | |
3 | 25 (46.30%) | 0.4424 (0.3024–1.234) | <0.0001 | |
Not available | 3 (5.56%) | |||
Stage | ||||
I | 17 (31.48%) | 1.287 (0.6117–2.809) | <0.0001 | 0.0523 |
II | 15 (27.78%) | 0.3205 (0.1722–1.8498 | <0.0001 | |
III | 11 (20.37%) | 0.4542 (0.2155–1.383) | 0.0026 | |
IV | 12 (22.22%) | 0.7656 (0.3475–1.934) | <0.0001 | |
T | ||||
T1 | 20 (37.04%) | 1.049 (0.4424–2.566) | <0.0001 | 0.2170 |
T2 | 15 (27.78%) | 0.6770 (0.3024–1.954) | <0.0001 | |
T3 | 11 (20.37%) | 0.2620 (0.0387–1.934) | 0.0089 | |
T4 | 5 (9.26%) | 0.7220 (0.3475–3.180) | <0.0001 | |
Not available | 3 (5.55%) | |||
N | ||||
Positive | 26 (48.15%) | 0.4774 (0.3024–1.288) | <0.0001 | 0.0584 |
Negative | 26 (48.15%) | 1.021 (0.4424–2.566) | <0.0001 | |
Not available | 2 (3.70%) | |||
Metastasis | ||||
Yes | 11 (20.37%) | 0.7656 (0.3475–1.934) | <0.0001 | 0.5168 |
No | 41 (75.93%) | 0.6612 (0.3753–1.287) | <0.0001 | |
Not available | 2 (3.70%) |
Characteristics | BC Patients | Healthy Controls |
---|---|---|
Number | 18 | 74 |
Median age in years (range) | 54 (34–69) | 55 (32–90) |
Molecular subtype, N (%) | ||
Luminal | 11 (61.11%) | |
TNBC | 3 (16.67%) | |
HER2 | 3 (16.67%) | |
Not available | 1 (5.55%) | |
Grade, N (%) | ||
1 | 5 (27.78%) | |
2 | 9 (50%) | |
3 | 4 (22.22%) | |
Stage, N (%) | ||
I | 18 (100%) | |
T, N (%) | ||
T1 | 18 (100%) | |
N, N (%) | ||
Positive | 18 (100%) | |
Metastasis, N (%) | ||
No | 18 (100%) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Adam-Artigues, A.; Garrido-Cano, I.; Carbonell-Asins, J.A.; Lameirinhas, A.; Simón, S.; Ortega-Morillo, B.; Martínez, M.T.; Hernando, C.; Constâncio, V.; Burgues, O.; et al. Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer. Cancers 2021, 13, 2848. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers13112848
Adam-Artigues A, Garrido-Cano I, Carbonell-Asins JA, Lameirinhas A, Simón S, Ortega-Morillo B, Martínez MT, Hernando C, Constâncio V, Burgues O, et al. Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer. Cancers. 2021; 13(11):2848. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers13112848
Chicago/Turabian StyleAdam-Artigues, Anna, Iris Garrido-Cano, Juan Antonio Carbonell-Asins, Ana Lameirinhas, Soraya Simón, Belén Ortega-Morillo, María Teresa Martínez, Cristina Hernando, Vera Constâncio, Octavio Burgues, and et al. 2021. "Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer" Cancers 13, no. 11: 2848. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers13112848